Jane Lowe Meisel, MD, presents data from a retrospective study investigating patient characteristics, treatment patterns, and clinical outcomes for tucatinib-based treatment in the real-world setting both overall and following fam-trastuzumab deruxtecan (T-DXd).
Drs Tripathy and Kaklamani emphasize the most critical unmet needs for patients with HER2+ metastatic breast cancer in the third-line or higher settings and recap what the field previously learned from the HER2CLIMB trial of tucatinib/trastuzumab/capecitabine.
Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.
Adrienne G. Waks, MD, spotlights the role of the HER2CLIMB regimen in patients with HER2-positive breast cancer with brain metastases, discusses unmet needs in the fourth- and later-line settings in HER2-positive disease, and explains the basis for the ongoing HER2CLIMB-02 and HER2CLIMB-04 trials within the broader ADC landscape.
Expert oncologist Virginia Kaklamani, MD, DSc, shares her perspectives on a patient case of HER2+ metastatic breast cancer (mBC) treated with multiple lines of therapy.
Stephanie L. Graff, MD, discusses data from an exploratory analysis of patients with HER2-positive breast cancer and brain metastases enrolled to the phase 2 HER2CLIMB study, and emphasizes the need for such research efforts to move the needle forward for this population.
- Exploratory Analyses from the Pivotal HER2CLIMB Trial Show Patients with Stable and Active Brain Metastases Treated with a TUKYSA Regimen Maintained a Survival Benefit After Additional 15.6 Months